GLP-1 medications
GLP-1 is a hormone your gut releases after you eat — it tells your brain you're full and helps your body manage blood sugar. GLP-1 medications (semaglutide, tirzepatide, and newer molecules) copy that signal, which is why they're so widely studied for weight management and metabolic health.
The articles below explain how these medications work, what the research actually shows, and what side effects and dosing schedules look like in practice. Promise offers compounded GLP-1 medications by prescription only: a licensed provider reviews every request, and not everyone qualifies.
331 articles on this topic
-

Zenagamtide: Amycretin’s New Name, Still in Trials
Zenagamtide is amycretin’s new name: an experimental drug being tested as a weekly shot and a daily pill. Here’s what the trials actually found.
-

Tirzepatide and Thyroid: Levothyroxine Checks
An underactive thyroid doesn't automatically rule out tirzepatide. Weight loss and changes in tablet absorption can make a thyroid-dose review worthwhile.
-

OASIS 4 Trial Results: 13.6% Weight Loss Explained
The daily 25 mg tablet averaged 13.6% weight loss versus 2.2% with placebo at 64 weeks. The 16.6% headline assumes continued treatment.
-

Does Semaglutide Cause Thyroid Cancer?
Human studies have not established that semaglutide causes thyroid cancer. The warning comes from tumors in rats and mice, and specific cancer histories rule out use.
-

What Does A1C Reduction Mean? A One-Point Drop
A one-point A1C drop means about 29 mg/dL less estimated average blood sugar. Its meaning depends on the starting number and how safely it falls.
-

What Is Bioequivalence? What Generics Must Match
Bioequivalence compares how two medicines reach the body. The 80–125% rule measures study uncertainty, and compounded drugs follow a different route.
-

STEP UP Trial Results: 7.2 mg Versus 2.4 mg
STEP UP compared two semaglutide doses with placebo over 72 weeks. The higher dose brought more weight loss and more stomach and skin symptoms.
-

Tirzepatide and Pancreatitis: Risk and Symptoms
Pancreatitis is uncommon in tirzepatide trials, but it remains a serious warning. Persistent or severe stomach pain needs urgent medical attention.
-

Semaglutide and Gallbladder: Risks and Symptoms
Gallstones were more common in semaglutide trials, but most participants did not report them. Here are the Wegovy and Ozempic rates and the symptoms that need urgent care.
-

STEP-HFpEF Results: Symptoms, Weight and Limits
Semaglutide improved symptoms and walking distance in two year-long trials of adults with obesity and heart failure. Here are the results, side effects and limits.
-

SURPASS-CVOT Results: What the Heart Trial Found
Tirzepatide met the trial’s standard for not being meaningfully worse than dulaglutide. It did not establish better heart outcomes.
-

Open Enrollment GLP-1 Coverage: 2027 Checklist
Coverage depends on the exact plan, product, and reason for prescribing. This fall's checklist covers dates, approval rules, refill costs, and Medicare's separate Bridge program.
-

Semaglutide for PCOS: Weight Loss and Periods
Semaglutide may help with weight loss in some people with PCOS. Evidence for more regular periods is growing, while pregnancy plans change the decision.
-

SURMOUNT-3 Results: More Weight Loss After Diet
After an average 6.9% loss through diet and exercise, selected trial participants lost another 18.4% on tirzepatide. Participants receiving an injection without tirzepatide gained 2.5% over the same 72 weeks.
-

Tirzepatide and Cholesterol: What the Numbers Mean
Trials found larger changes in some blood fats than in the cholesterol linked to artery buildup. Here is what those percentages mean on a lab report.
-

Gila Monster Weight Loss Drug: The Byetta Story
Gila monster venom supplied the blueprint for exenatide, first marketed as Byetta. Semaglutide and tirzepatide are different, manufactured designs.
-

STEP 4 Trial Results: Regain After Wegovy Stops
After 20 weeks on semaglutide, people who continued lost more weight. Those switched to placebo regained weight despite continued lifestyle support; who reached that switch shapes the answer.
-

What Is an Estimand? Why Trials Report Two Numbers
Two weight-loss numbers from one study can both be right. The difference is often whether the calculation includes treatment stops or assumes continued treatment.
-

SOUL Trial Results: Oral Semaglutide and the Heart
Over about four years, fewer people taking a daily semaglutide tablet had a heart attack, stroke or cardiovascular death than people on placebo. Here is who was in the trial, what it counted, and what it can't tell you.
-

SUSTAIN-6 Results: Ozempic's Heart and Eye Trial
The 2016 trial that checked semaglutide's heart safety found fewer major heart events than placebo, and an eye-complication signal that still shapes the label today.
Page 6 of 17 · 331 articles